

# Process for requesting inclusion of off-label information in Micromedex databases

Micromedex® is recognized worldwide as a provider of unbiased information in the areas of drugs, disease, and toxicology. Our Micromedex Drug Information content is evidence-based medicine whereby the clinician can identify best practices and choose the most appropriate treatment plan for a specific patient.

The proprietary, unbiased information contained in Micromedex Drug Information is based on an ongoing editorial review of primary literature published in thousands of peer-reviewed journals, as well as FDA-approved product labeling. Inclusion of information is determined through identification of relevant literature and through the use of validated and documented literature evaluation techniques that assess methodological rigor, appropriateness of statistical analyses, and clinical relevance. Our surveillance of the literature is extensive and continuous.

© Copyright Merative U.S.L.P. 2023  
Merative  
100 Phoenix Drive  
Ann Arbor, Michigan 48108

Produced in the United States of America  
December 2023

Merative, the Merative logo and Micromedex are trademarks of Merative in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies.

This document is current as of the initial date of publication and may be changed by Merative at any time. Not all offerings are available in every country in which Merative operates.

The information in this document is provided "as is" without any warranty, express or implied, including without any warranties of merchantability, fitness for a particular purpose and any warranty or condition of non-infringement. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

The client is responsible for ensuring compliance with all applicable laws and regulations applicable to it. Merative does not provide legal advice or represent or warrant that its services or products will ensure that the client is in compliance with any law or regulation. The performance data and client examples cited are presented for illustrative purposes only. Actual performance results may vary depending on the specific configurations and operating conditions. It is the user's responsibility to evaluate and verify the operation of any other products or programs with Merative product and programs.

Statement of Good Security Practices: IT system security involves protecting systems and information through prevention, detection and response to improper access from within and outside your enterprise. Improper access can result in information being altered, destroyed, misappropriated or misused or can result in damage to or misuse of your systems, including for use in attacks on others. No IT system or product should be considered completely secure and no single product, service or security measure can be completely effective in preventing improper use or access. Merative systems, products and services are designed to be part of a lawful, comprehensive security approach, which will necessarily involve additional operational procedures, and may require other systems, products or services to be most effective. Merative does not warrant that any systems, product or services are immune from, or will make your enterprise immune from, the malicious or illegal conduct of any party.

## External requests for inclusion of information

In addition to rigorous internal processes, Merative occasionally receives external requests for inclusion of information in our Micromedex databases. We adhere to a policy under which external requests may be submitted for consideration. Please forward one complete bibliography of information to be considered via email( [productsupport@merative.com](mailto:productsupport@merative.com) ) or in writing.

This request must include the following:

- Name of requestor
  - Date of submission
  - Affiliation of requestor (e.g., name of pharmaceutical company, organization, institution, etc.)
  - Disclosure of relevant financial relationships with a bearing on the drug(s) or product(s) in question
  - Contact information including address, phone number, and email address
  - Identification and brief explanation of request (should clearly indicate if request involves a patient safety issue)
- If applicable, a statement describing the proposed indication including:
    - Specific disease state
    - Specific patient population
    - Whether the treatment involves mono- or combination therapy
  - If the treatment involves combination therapy, address specific components of the therapy

We are unable to provide any feedback or response regarding any literature/evidence submitted. All requests will be reviewed in accordance with established policies on content development, including the Policy on Off-Label Indications. Furthermore, if submitted information warrants inclusion in Micromedex databases, we cannot provide the requestor with a prepublication copy of text. Finally, the inclusion or exclusion of information in our databases, as well as assignment of an efficacy rating or other relevant ratings, are at the sole discretion of our editorial staff.

Merative reserves the right to modify its policy on requesting inclusion of information in its databases as deemed appropriate.

## About Merative

Merative provides data and software for healthcare and government social services. With focused innovation and deep expertise, Merative works with providers, employers, health plans, governments, and life science companies to drive real progress. Merative helps clients orient information and insights around the people they serve to improve decision-making and performance. Merative, formerly IBM Watson Health, became a new standalone company as part of Francisco Partners in 2022. Learn more at [merative.com](https://merative.com).

